May 13, 2016
1 min read

Improvements seen after reverse PAO for patients with FAI secondary to acetabular retroversion

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

At mid- and long-term follow-up, clinical and radiographic results improved among young patients with either isolated retroversion or retroversion and hip dysplasia who underwent reverse periacetabular osteotomy for treatment of femoroacetabular impingement.

Researchers performed a retrospective review to identify 23 patients with femoroacetabular impingement secondary to acetabular retroversion and treated with reverse periacetabular osteotomy. Of the 30 hips, 10 had retroversion and dysplasia and the remaining had isolated retroversion. Preoperatively and at the last follow-up, investigators evaluated patients’ radiographs and Harris hip scores (HHS). The average follow-up for the study was 5 years.  

Results showed the average HHS in patients with isolated retroversion increased from 58 points preoperatively to 93 points at latest follow-up and increased from 49 points to 92 points, respectively, in patients with dysplastic hips. The mean preoperative lateral center-edge angle in the isolated retroversion group and dysplastic hip group was 31° and 9°, respectively, with the angle increasing to 35° in both groups at the last follow-up.

According to researchers, radiographs showed the crossover sign was corrected in 55% of the isolated retroversion group vs. 80% for the dysplastic hip group. The acetabular index significantly increased in both groups, which demonstrated the acetabular anterversion improved postoperatively. Investigators noted the groups had similar complication rates, with four hips requiring additional surgery when investigators excluded cases of hardware removal. ‒ by Monica Jaramillo


Disclosures: The researchers report no relevant financial disclosures.